Kyverna Therapeutics, Inc.
KYTXDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
4
Next Catalyst
Apr 1, 2026
4dMarket Overview
Stock performance and key metrics
4 upcoming, 3 past
Conference Presentation
Kyverna Therapeutics will present new data from its neuroimmunology franchise at the 2026 American Academy of Neurology (AAN) annual meeting. The announcement provides a routine update on the company's pipeline progress.
3 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Standard lymphodepletion regimen
Lupus Nephritis
Standard of Care Treatment
Myasthenia Gravis
KYV-101
Systemic Sclerosis
KYV-101 anti-CD19 CAR-T cell therapy
Lupus Nephritis
Anti-CD20 mAB
Multiple Sclerosis, Primary Progressive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Standard lymphodepletion regimen | Phase 3 | Lupus Nephritis | - | - |
Standard of Care Treatment | Phase 3 | Myasthenia Gravis | - | - |
KYV-101 | Phase 3 | Systemic Sclerosis | - | - |
KYV-101 anti-CD19 CAR-T cell therapy | Phase 2 | Lupus Nephritis | - | - |
Anti-CD20 mAB | Phase 2 | Multiple Sclerosis, Primary Progressive | - | - |